Commentary:

           Established in 2005, the company was one of the well-known aesthetic medical service provider in Hong Kong. Operating under the brand name, DR REBORN, the brand developed into one of the popular aesthetic medical provider in Hong Kong. Building on their success of DR REBORN, the company began to diversify into medical, dental as well as other medical services. After series of acquisition and consolidation, the company's services are now composed of the following: Medical services, Aesthetic medical and beauty and welless services and Others. As at 30 September 2022, the company operated 154 services points in Hong Kong, Macau and Mainland China.

           The company released its 2022 interim result (year ended on 30th September) on the 24^th of November, the table below briefly summarised the company's performance:

Source: Company's annual reports and interim reports

           Overall, the company's revenue was up 31.1% y-o-y to HK$1,893.2 M. However, EBITDA  was down 16.6% y-o-y to HK$269.9M and the net profit was down 46.3% y-o-y to HK$105.2M. The decline could be contributed to the challenging condition including uncertainity in the global economy, indefinite re-opening time of the border and weak retail data due to persisting COVID-19. In terms of geograhic contribution, Hong Kong reported revenue HK$1,746.5M, up 33.2% y-o-y and representing approximately 92.3% of the group's overall revenue, while Macau reported revenue HK$ 56.8M, up 7.7% y-o-y and Mainland China had HK$ 89.8M, up 12.6% y-o-y.

Overall financial summry of the company from 2018 to 2022:

Source: Company's annual reports

Companies comparison (14/12/2022)